Microbot Medical Receives Notice of Allowance for U.S. Patent Covering a System for Reducing Dialysis Shunt Stenosis
October 07 2020 - 7:00AM
Microbot Medical Inc. (Nasdaq: MBOT) announced that the United
States Patent and Trademark Office (USPTO) has issued a Notice of
Allowance for patent application No. 15/592,227, which pertains to
a device for reducing dialysis shunt stenosis. The allowed patent
application is a Continuation of Patent No. 9,675,748, which was
issued on June 13, 2017.
“This latest patent allowance demonstrates the
continued solid execution of our IP portfolio strategy,” commented
Harel Gadot, Chief Executive Officer, President and Chairman.
“Expanding and protecting our innovative technologies remains a
primary objective and we intend to be proactive to ensure a
sustainable, competitive advantage for our products.”
The allowed patent application covers a system
for reducing venous stenosis associated with the use of
hemodialysis shunts. A clearing device is inserted into the blood
vessel through a first needle bore, while dialyzed blood is
returned into the blood vessel through a second needle bore. The
clearing device can be actuated from externally to the patient’s
body. The clearing device is adapted to move autonomously, and it
may be an autonomous crawling device, such as the Company’s TipCat™
device, which is based on a series of sequentially inflatable
chambers. This allowance adds an additional layer of protection
beyond the current IP protected applications of Microbot's TipCat™
and ViRob™ platforms.
Globally, the Company now has a total of 39
issued/allowed patents and 23 patent applications pending
worldwide.
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a
pre-clinical medical device company that specializes in
transformational micro-robotic technologies, focused primarily on
both natural and artificial lumens within the human body.
Microbot’s current proprietary technological platforms provide the
foundation for the development of a Multi Generation Pipeline
Portfolio (MGPP).
Microbot Medical was founded in 2010 by Harel
Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of
improving clinical outcomes for patients and increasing
accessibility through the use of micro-robotic technologies.
Further information about Microbot Medical is available at
http://www.microbotmedical.com.
Safe Harbor
Statements pertaining to the registered direct
offering, timing, the amount and anticipated use of proceeds and
statements pertaining to future financial and/or operating results,
future growth in research, technology, clinical development, and
potential opportunities for Microbot Medical Inc. and its
subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management, constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 and
the Federal securities laws. Any statements that are not historical
fact (including, but not limited to statements that contain words
such as “will,” “believes,” “plans,” “anticipates,” “expects” and
“estimates”) should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, market conditions and
the satisfaction of customary closing conditions, risks inherent in
the development and/or commercialization of potential products,
including LIBERTY, the outcome of its studies to evaluate the SCS
and other existing and future technologies, uncertainty in the
results of pre-clinical and clinical trials or regulatory pathways
and regulatory approvals, uncertainty resulting from the COVID-19
pandemic, need and ability to obtain future capital, and
maintenance of intellectual property rights. Additional information
on risks facing Microbot Medical can be found under the heading
“Risk Factors” in Microbot Medical’s periodic reports filed with
the Securities and Exchange Commission (SEC), which are available
on the SEC’s web site at www.sec.gov. Microbot Medical disclaims
any intent or obligation to update these forward-looking
statements, except as required by law.
Investor Contact:
Michael PolyviouEVC Groupmpolyviou@evcgroup.com732-933-2754
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Apr 2023 to Apr 2024